Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

EpiPen Generics: Woodcock Explains Injector Studies

Executive Summary

In response to Congressional questions about whether FDA is a barrier to competition for the epinephrine product, CDER Director lays out what could be required to prove an injector device problem is fixed.


Related Content

EpiPen Rival Heads Back To Market After kaléo Retools With ‘100% Automated’ Production
ANDAs For Drug/Device Combos Face High Bar At US FDA; Epipen, Advair May Benefit
Sarepta's Shadow: BioMarin Mulls Turning The Extraordinary Into A Template
ANDA Approvals, Complete Responses Hit Record In FY 2016
Scrutiny Of EpiPen Pricing Invited By Mylan Lobbying, Congressman Says
EpiPen Familiarity May Prove Tough Hurdle For Generics
Mylan's EpiPen Nightmare Not Over Yet, But Will Congress Just Write?
Drug Pricing Panacea Or Just PR Victory? Expedited ANDAs May Have Limited Impact
Mylan’s EpiPen Exclusivity Saved Again As Teva Reports CRL
Mylan’s EpiPen Defense Against Generics Focuses On Device Design


Related Companies